196 related articles for article (PubMed ID: 22156337)
1. Cellular prion protein mediates toxic signaling of amyloid beta.
Resenberger UK; Winklhofer KF; Tatzelt J
Neurodegener Dis; 2012; 10(1-4):298-300. PubMed ID: 22156337
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurotoxic signaling by the prion protein.
Resenberger UK; Winklhofer KF; Tatzelt J
Top Curr Chem; 2011; 305():101-19. PubMed ID: 21598098
[TBL] [Abstract][Full Text] [Related]
3. Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death.
Cronier S; Carimalo J; Schaeffer B; Jaumain E; Béringue V; Miquel MC; Laude H; Peyrin JM
FASEB J; 2012 Sep; 26(9):3854-61. PubMed ID: 22661006
[TBL] [Abstract][Full Text] [Related]
4. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
[TBL] [Abstract][Full Text] [Related]
5. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.
Resenberger UK; Harmeier A; Woerner AC; Goodman JL; Müller V; Krishnan R; Vabulas RM; Kretzschmar HA; Lindquist S; Hartl FU; Multhaup G; Winklhofer KF; Tatzelt J
EMBO J; 2011 May; 30(10):2057-70. PubMed ID: 21441896
[TBL] [Abstract][Full Text] [Related]
6. Interaction between misfolded PrP and the ubiquitin-proteasome system in prion-mediated neurodegeneration.
Lin Z; Zhao D; Yang L
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):477-84. PubMed ID: 23449072
[TBL] [Abstract][Full Text] [Related]
7. An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells.
Kazlauskaite J; Young A; Gardner CE; Macpherson JV; Vénien-Bryan C; Pinheiro TJ
Biochem Biophys Res Commun; 2005 Mar; 328(1):292-305. PubMed ID: 15670783
[TBL] [Abstract][Full Text] [Related]
8. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
Leliveld SR; Stitz L; Korth C
Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
[TBL] [Abstract][Full Text] [Related]
9. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
[TBL] [Abstract][Full Text] [Related]
10. X-ray diffraction analysis of scrapie prion: intermediate and folded structures in a peptide containing two putative alpha-helices.
Inouye H; Kirschner DA
J Mol Biol; 1997 May; 268(2):375-89. PubMed ID: 9159477
[TBL] [Abstract][Full Text] [Related]
11. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
12. Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons.
Gavín R; Ureña J; Rangel A; Pastrana MA; Requena JR; Soriano E; Aguzzi A; Del Río JA
Neurobiol Dis; 2008 May; 30(2):243-54. PubMed ID: 18374587
[TBL] [Abstract][Full Text] [Related]
13. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of prion diseases.
Unterberger U; Voigtländer T; Budka H
Acta Neuropathol; 2005 Jan; 109(1):32-48. PubMed ID: 15645262
[TBL] [Abstract][Full Text] [Related]
15. Prion encephalopathies of animals and humans.
Prusiner SB
Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
[TBL] [Abstract][Full Text] [Related]
16. Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein.
Wille H; Prusiner SB; Cohen FE
J Struct Biol; 2000 Jun; 130(2-3):323-38. PubMed ID: 10940236
[TBL] [Abstract][Full Text] [Related]
17. Antiprion properties of prion protein-derived cell-penetrating peptides.
Löfgren K; Wahlström A; Lundberg P; Langel U; Gräslund A; Bedecs K
FASEB J; 2008 Jul; 22(7):2177-84. PubMed ID: 18296502
[TBL] [Abstract][Full Text] [Related]
18. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
[TBL] [Abstract][Full Text] [Related]
19. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.
Lührs T; Zahn R; Wüthrich K
J Mol Biol; 2006 Mar; 357(3):833-41. PubMed ID: 16466741
[TBL] [Abstract][Full Text] [Related]
20. The possible role of protein X, a putative auxiliary factor in pathological prion replication, in regulating a physiological endoproteolytic cleavage of cellular prion protein.
Hachiya NS; Imagawa M; Kaneko K
Med Hypotheses; 2007; 68(3):670-3. PubMed ID: 17008028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
